Lucrezia Hausner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11677690/publications.pdf

Version: 2024-02-01

44 papers 3,720 citations

331259 21 h-index 301761 39 g-index

44 all docs

44 docs citations

44 times ranked 5535 citing authors

#	Article	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
3	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	3.0	419
4	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Molecular Neurodegeneration, 2014, 9, 53.	4.4	216
5	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
6	Association of Cerebral Amyloid- \hat{l}^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
7	Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) in Depressed Elderly Inpatients With Coexisting Mild Cognitive Impairment or Dementia. Journal of Clinical Psychiatry, 2011, 72, 91-97.	1.1	98
8	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
9	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusionâ€₹ensor and Magnetic Resonance Imaging Data. Journal of Neuroimaging, 2015, 25, 738-747.	1.0	79
10	Detection of Retinal Nerve Fiber Layer Defects in Alzheimer's Disease Using SD-OCT. Frontiers in Psychiatry, 2014, 5, 22.	1.3	77
11	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment – A Multicenter DTI and Volumetry Study. Journal of Alzheimer's Disease, 2015, 48, 197-204.	1.2	56
12	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
13	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	1.8	43
14	The European DTI Study on Dementia â€" A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308.	2.1	33
15	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
16	Development of a Proxy-Free Objective Assessment Tool of Instrumental Activities of Daily Living in Mild Cognitive Impairment Using Smart Home Technologies. Journal of Alzheimer's Disease, 2016, 52, 509-517.	1.2	32
17	Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning. Alzheimer's Research and Therapy, 2017, 9, 22.	3.0	31
18	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	0.9	31

#	Article	lF	CITATIONS
19	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
20	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	1.2	27
21	Comparison of Visual Evoked Potentials and Retinal Nerve Fiber Layer Thickness in Alzheimer's Disease. Frontiers in Neurology, 2013, 4, 203.	1.1	21
22	Electroconvulsive therapy selectively enhances amyloid \hat{l}^2 $1\hat{a}$ \in "42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology, 2016, 26, 1877-1884.	0.3	20
23	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	1.3	19
24	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
25	Bupropion for the Treatment of Apathy in Alzheimer Disease. JAMA Network Open, 2020, 3, e206027.	2.8	18
26	Severe agitation in severe early-onset Alzheimer's disease resolves with ECT. Neuropsychiatric Disease and Treatment, 2014, 10, 2147.	1.0	14
27	Evaluation of Sodium (²³ Na) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer's Disease. In Vivo, 2021, 35, 429-435.	0.6	14
28	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	1.4	14
29	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
30	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 124.	3.0	12
31	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. Journal of Alzheimer's Disease, 2010, 21, 155-165.	1.2	10
32	Separating Symptomatic Alzheimer's Disease from Depression based on Structural MRI. Journal of Alzheimer's Disease, 2018, 63, 353-363.	1.2	10
33	Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. , 2014 , 10 , $e27$ - $e39$.		9
34	Lateâ€onset major depression is associated with ageâ€related white matter lesions in the brainstem. International Journal of Geriatric Psychiatry, 2017, 32, 446-454.	1.3	7
35	Case report: a giant arachnoid cyst masking Alzheimer's disease. BMC Psychiatry, 2019, 19, 274.	1.1	7
36	Tablet-based sensorimotor home-training system for amnestic mild cognitive impairments in the elderly: design of a randomised clinical trial. BMJ Open, 2019, 9, e028632.	0.8	5

#	Article	IF	CITATIONS
37	Crossed Cerebellar Diaschisis in Alzheimer's Disease Detected by Arterial Spin-labelling Perfusion MRI. In Vivo, 2021, 35, 1177-1183.	0.6	5
38	Promoting neuroplasticity and neuropsychological functioning in frailty through an app-based sensorimotor training: study protocol for a randomized trial. BMC Geriatrics, 2021, 21, 343.	1.1	3
39	Should electroconvulsive therapy be more routinely used in the treatment of depression in elderly patients with cognitive disturbances?. Neuropsychiatry, 2011, 1, 403-407.	0.4	1
40	IC-P-072: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY. , 2014, 10, P40-P40.		1
41	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY. , 2014, 10, P400-P401.		1
42	Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline. Geriatrics (Switzerland), 2021, 6, 30.	0.6	1
43	P1â€298: CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYSOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID Aβâ€42 AND <i>Pâ€7AU</i> Alzheimer's and Dementia, 2018, 14, P403.	0.4	0
44	6 .Diagnostische Methoden. , 2018, , 187-352.		0